Page 173 - CW E-Magazine (24-9-2024)

Special Report

Service type trends in CRO industry Ltd., and Syngene International Ltd., is capabilities in biomarker identification,
further supporting segment growth in validation, and application, as well as
Clinical Development to lead among India. offering services related to companion
CRO Service areas diagnostic development and testing.
Clinical trial management ser- Pre-Clinical CROs to face tough These services enable pharmaceuti-
vices continue to be a core offering times ahead cal companies to better stratify patient
in the contract research industry. For Preclinical CROs typically use ani- populations, improve clinical trial out-
the forecasted global pharmaceutical mals like rats, mice, guinea-pigs, rab- comes, and develop precision therapies.
DRO market of $90.4-bn by 2030, it bits, canines, bovines or non-human AstraZeneca announced a strategic
is estimated that $61.2-bn (approxi- primates in testing the drugs for check- research collaboration with Illumina,
mately 67%) will be contributed only ing the safety profiles. In 2022, 42 a global pioneer in DNA sequencing and
by the outsourcing done in the domain countries worldwide have banned or array-based technologies. This collabo-
of clinical development services. With restricted cosmetic animal testing, in- ration aimed to expedite drug target
drugs worth $251-bn going off-patent cluding all 27 countries in the EU, Aus- discovery by melding their respective
by the year 2030, the Indian clinical tralia, Colombia, Guatemala, Iceland, competencies in AI-based genome inter-
CROs operating in Bioequivalence and India, Israel, Mexico, New Zealand, pretation and genomic analysis. The
Bioavailability services have numerous Norway, South Korea, Switzerland, initiative will examine if a unified ap-
opportunities to capitalize on. Taiwan, Turkey, and the UK. In India, proach utilizing these technologies can
a recent amendment to the New Drugs bolster the efficiency and certainty of
Surge in demand for Discovery and Clinical Trial Rules (2023), passed target discovery in pursuit of promising
Chemical Services by the Government of India, aims to drugs built upon human omics insights.
The global drug discovery outsour- replace the use of animals in research, AstraZeneca’s Centre for Genomics
cing market, which was valued at especially in drug testing. The amend- Research will adopt a framework
$3.8-bn in the year 2022, is increasing at a ment authorises researchers to instead merging the AI-based tools of both
CAGR of 7.3% and is expected to reach use non-animal and human-relevant companies, leveraging next-generation
$6.2-bn by 2031. On the basis of ser- methods, including technologies like AI interpretation tools like Illumina’s
vice type, the market is segmented into 3D organoids, organs-on-chip, and ad- PrimateAI and SpliceAI, along with
biology services and chemical services. vanced computational methods, to test AstraZeneca’s own tools such as
Gene editing, stem cells, immunothera- the safety and efficacy of new drugs. JARVIS and in silico predictors.
pies and new types of biologics are
now mega-trends in the pharmaceutical Building the scientific writing and Therapeutic area trends in CRO
industry. However, there are several hot regulatory capabilities industry
areas in small molecule drug discovery, The regulatory landscape in the While the top 20 pharma activity
suggesting a lot of untapped potential pharmaceutical industry is constantly for the major therapeutic areas in India
and investment prospects in this more evolving, with stricter and unhar- has remained largely constant in the
“traditional” pharmaceutical research monized regulations and guidelines. last decade, growth opportunities exist
space. The Discovery Chemical Seg- CROs are expanding their high-quality across key diseases (e.g., pain, epilepsy,
ment, focussed on small molecules has medical writing, documentation and cervical cancer) and orphan diseases
accounted for largest market share in regulatory capabilities to assist pharma- (β-thalassemia, Duchenne Muscular
2022. This trend is expected to continue ceutical companies in navigating Dystrophy).
till 2030. Biology services is expected region-specific complex regulatory
to witness the fastest growth of 7.5% requirements, ensuring compliance, Oncology
from 2023 to 2030. The growing and expediting the regulatory approval Oncology continues to be a domi-
demand for technical experts to conduct process. nant therapeutic area in pharmaceuti-
drug discovery services while abiding cal contract research. As per a study
by regulatory requirements is one Emergence biomarker and companion conducted in 2023, oncology segment
of the key factors promoting segment diagnostics services held more than 53.9% Asia Pacific
growth. Furthermore, the presence of a The use of biomarkers and compa- market share in 2021, due to growing
significant number of biology drug dis- nion diagnostics has gained prominence incidences of cancer. Moreover, rise in
covery service providers, such as Euro- in personalized medicine and targeted the number of oncology CRO services
fins, Aurigene Pharmaceutical Services therapies. CROs are expanding their in the region is another contributing

Chemical Weekly September 24, 2024 173

Contents Index to Advertisers Index to Products Advertised